irinotecan has been researched along with Brain Stem Neoplasms, Primary in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Browd, SR; Cole, BL; Crotty, EE; Ellenbogen, RG; Ermoian, RP; Geyer, JR; Hauptman, JS; Leary, SES; Lee, A; Lockwood, CM; Millard, NE; Ojemann, JG; Olson, JM; Paulson, VA; Sato, AA; Vitanza, NA | 1 |
| Chi, SN; Cohen, KJ; DiRenzo, J; Donson, AM; Dunkel, IJ; Etzl, MM; Foreman, NK; Gore, L; Kieran, MW; Kuei, MC; MacDonald, TJ; Macy, ME; Narendran, A; Ostrovnaya, I; Smith, AA; Trippett, TM | 1 |
| Bankiewicz, K; Drummond, DC; Goldman, S; Gupta, N; Hashizume, R; He, X; Liu, S; Louis, N; Mueller, S; Noble, CO | 1 |
| Blüml, S; Brown, RJ; Dhall, G; Finlay, JL; Wellner, M; Zaky, W | 1 |
| Backus, L; Chow, LM; DeWire, M; Doughman, R; Drissi, R; Fouladi, M; Goldman, S; Grimme, L; Hummel, TR; Kumar, S; Lane, A; Leach, J; Miles, L; Pai, A; Pruitt, D; Salloum, R; Sobo, M; Stevenson, C; Sutton, M | 1 |
| Loutfi, R; Mikkelsen, T; Torcuator, R; Zuniga, R | 1 |
| Boyett, JM; Chi, SN; Friedman, HS; Gilbertson, RJ; Gururangan, S; Kun, LE; Onar-Thomas, A; Packer, RJ; Rood, BN; Vajapeyam, S; Young Poussaint, T | 1 |
| Bowers, DC; Broniscer, A; Chintagumpala, M; Fouladi, M; Gajjar, A; Iacono, L; Krasin, MJ; Stewart, C; Wallace, D | 1 |
| Hasegawa, Y; Ishikawa, K; Kajita, Y; Nabeshima, T; Noda, Y; Yoshida, J | 1 |
2 trial(s) available for irinotecan and Brain Stem Neoplasms, Primary
| Article | Year |
|---|---|
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Brain Stem Neoplasms; Camptothecin; Child; Diffusion Magnetic Resonance Imaging; Glioma; Humans; Irinotecan; Neoplasm Recurrence, Local; Phosphorylation; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2010 |
Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Camptothecin; Child; Child, Preschool; Dacarbazine; Female; Glioma; Humans; Infusions, Intravenous; Irinotecan; Male; Temozolomide; Treatment Outcome | 2005 |
7 other study(ies) available for irinotecan and Brain Stem Neoplasms, Primary
| Article | Year |
|---|---|
Children with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Child; Child, Preschool; Diffuse Intrinsic Pontine Glioma; Female; Follow-Up Studies; Glioma; Humans; Infant; Irinotecan; Male; Neoplasm Grading; Retrospective Studies; Survival Rate; Temozolomide | 2020 |
A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Stem Neoplasms; Camptothecin; Cetuximab; Chemoradiotherapy; Child; Child, Preschool; Combined Modality Therapy; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Neoplasm Staging; Prognosis; Survival Rate; Young Adult | 2017 |
New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model.
Topics: Administration, Intranasal; Animals; Brain Stem Neoplasms; Cell Line, Tumor; Convection; Drug Carriers; Humans; Irinotecan; Liposomes; Male; Nanostructures; Rats; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2018 |
Treatment of children with diffuse intrinsic pontine gliomas with chemoradiotherapy followed by a combination of temozolomide, irinotecan, and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Disease-Free Survival; Female; Glioma; Humans; Irinotecan; Male; Radiography; Retrospective Studies; Survival Rate; Temozolomide | 2013 |
A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Camptothecin; Chemoradiotherapy; Child; Child, Preschool; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Irinotecan; Male; Neoplasm Grading; Pilot Projects; Prognosis; Survival Rate; Temozolomide; Young Adult | 2016 |
Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Stem Neoplasms; Camptothecin; Combined Modality Therapy; Female; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Radiotherapy | 2009 |
Irinotecan therapy in a 12-year-old girl with recurrent brain stem glioma and without functional polymorphisms in UGT1A1 activity: case report.
Topics: Antineoplastic Agents, Phytogenic; Brain Stem Neoplasms; Camptothecin; Child; Diarrhea; Female; Glioma; Glucuronosyltransferase; Humans; Irinotecan; Leukopenia; Magnetic Resonance Imaging; Polymorphism, Genetic | 2005 |